Y. Iino et al., RELATIONSHIP BETWEEN THYROID PITUITARY-FUNCTION AND RESPONSE TO THERAPY IN PATIENTS WITH RECURRENT BREAST-CANCER, Anticancer research, 16(4A), 1996, pp. 2069-2072
In this study, thyroid (T3, T4, free T3, free T4) and pituitary functi
on (thyrotropin (TSH), growth hormone (GH), prolactin (PRL)) in 38 pat
ients with recurrent breast cancer were examined. The patients were di
vided into three group according to their response to the therapy. The
re were 16 partial response (PR), 10 no change (NC) and 11 progressive
disease (PD) patients. The maximum and minimum value for each hormone
throughout the course of treatment were compared between three groups
. The PD group showed significantly lower minimum T3 levels than the o
ther two groups (p < 0.05). The maximum TSH level in the PD group was
significantly higher than that of the other groups. The minimum TSH le
vel in the PD group was significantly lower that that in the PR group
(p < 0.05). The minimum TSH level in the NC group was also lower than
that in the PR group. The maximum PRL level in the NC and the PD group
was higher than that in the PR group (p < 0.05, p < 0.01, respectivel
y). The tumors of the patients with temporal increase of TSH level wer
e resistant to all subsequent therapies. These five patients died with
in four months followed by decreasing of the TSH level. It is conclude
d that thyroid and pituitary function, especially free T4, TSH and PRL
, are predictive indicators of therapeutic response and the prognosis
of the patients with recurrent breast cancer.